Nexstim received a new sales authorization for the NBS 6 system in Australia
Summary
- Nexstim has received marketing authorization from the Australian health authority for its NBS 6 system, expanding its use to diagnostics and post-surgical rehabilitation.
- This authorization complements previous approvals for treating depression and chronic pain, allowing the system to be marketed for mapping motor and speech cortices and treating post-stroke motor disorders.
- The NBS 6 system already has similar approvals in Europe and the US, and this expansion into Australia is part of Nexstim's strategy to grow beyond its main markets.
- Despite the new authorization, growth is expected to continue relying on the US and European markets, with potential expansion into markets like Japan.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 06/04/2026 at 08:11 am EEST
Nexstim announced on Wednesday that it had received marketing authorization from the Australian health authority (TGA) for its NBS 6 system for diagnostics and post-surgical rehabilitation. The authorization complements the company's previous Australian marketing authorization for the treatment of depression and chronic pain. With the new authorization, the company can begin marketing the system for mapping the motor and speech cortices and for the treatment of post-stroke motor disorders in adult patients. The NBS 6 system has already received similar approvals in the company's main markets in Europe and the United States. The news is a welcome step as the company gradually expands its operations beyond its main markets of the US and Europe.
The company's partner Brainlab is largely responsible for the distribution of the diagnostics business, for which new approvals create a basis for long-term growth in the installed base. However, we expect growth in the coming years to continue to rely primarily on the US and European markets, as well as potential new openings, for example, in Japan.
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures14/05
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 11.0 | 12.7 | 16.1 |
| growth-% | 25.5 % | 15.7 % | 26.8 % |
| EBIT (adj.) | 0.6 | 1.2 | 2.3 |
| EBIT-% (adj.) | 5.8 % | 9.5 % | 14.1 % |
| EPS (adj.) | 0.08 | 0.12 | 0.27 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | 123.3 | 78.9 | 36.7 |
| EV/EBITDA | 43.0 | 31.3 | 20.4 |
Forum discussions
